Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse
- PMID: 28418909
- PMCID: PMC5471068
- DOI: 10.18632/oncotarget.16367
Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse
Abstract
ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL). Multiple lines of evidence imply a "two-hit" model for the molecular pathogenesis of E/R-positive ALL, whereby E/R rearrangement is followed by a series of secondary mutations that trigger overt leukemia. The cellular framework in which E/R arises and the maintenance of a pre-leukemic condition by E/R are fundamental to the mechanism that underlies leukemogenesis. Accordingly, a variety of studies have focused on the relationship between the clones giving rise to the primary and recurrent E/R-positive ALL. We review here the most recent insights into the pathogenic mechanisms underlying E/R-positive ALL, as well as the molecular abnormalities prevailing at relapse.
Keywords: ETV6/RUNX1; childhood acute lymphoblastic leukemia; initiation; mechanisms; relapse.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21).Cells. 2023 Jan 18;12(3):357. doi: 10.3390/cells12030357. Cells. 2023. PMID: 36766699 Free PMC article. Review.
-
Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.Haematologica. 2014 Apr;99(4):706-14. doi: 10.3324/haematol.2012.072470. Epub 2013 Nov 15. Haematologica. 2014. PMID: 24241490 Free PMC article.
-
High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.Pediatr Blood Cancer. 2019 Aug;66(8):e27780. doi: 10.1002/pbc.27780. Epub 2019 Apr 29. Pediatr Blood Cancer. 2019. PMID: 31034759
-
Outcome and Prognostic Factors for ETV6/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea.Cancer Res Treat. 2017 Apr;49(2):446-453. doi: 10.4143/crt.2016.211. Epub 2016 Aug 10. Cancer Res Treat. 2017. PMID: 27506214 Free PMC article.
-
ETV6-RUNX1 + Acute Lymphoblastic Leukaemia in Identical Twins.Adv Exp Med Biol. 2017;962:217-228. doi: 10.1007/978-981-10-3233-2_14. Adv Exp Med Biol. 2017. PMID: 28299660 Review.
Cited by
-
The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21).Cells. 2023 Jan 18;12(3):357. doi: 10.3390/cells12030357. Cells. 2023. PMID: 36766699 Free PMC article. Review.
-
ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.Cells. 2020 Jan 15;9(1):215. doi: 10.3390/cells9010215. Cells. 2020. PMID: 31952221 Free PMC article.
-
Prognostic Impact of Copy Number Alterations' Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy.Cancers (Basel). 2023 Nov 15;15(22):5431. doi: 10.3390/cancers15225431. Cancers (Basel). 2023. PMID: 38001691 Free PMC article.
-
Novel RUNX1 Variation in B-cell Acute Lymphoblastic Leukemia.Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023036. doi: 10.4084/MJHID.2023.036. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37435033 Free PMC article.
-
Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives.Hematol Rep. 2025 Mar 28;17(2):18. doi: 10.3390/hematolrep17020018. Hematol Rep. 2025. PMID: 40277842 Free PMC article. Review.
References
-
- Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995;85:3662–70. - PubMed
-
- Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources